Estrella Immunopharma, Inc. (ESLA) vs Kyntra Bio, Inc. (KYNB)
A side-by-side comparison of Estrella Immunopharma, Inc. and Kyntra Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.41HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
KYNB
Kyntra Bio, Inc.
$5.95HealthcareDelayed quote: Oct 6, 2026, 12:49 PM EDT
Total return — ESLA vs KYNB
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)KYNB -97.9% (-53.6%/yr)ESLA compounded faster over this window
ESLA KYNB
ESLA vs KYNB: by the numbers
- •KYNB is the larger company ($24M vs $18M market cap).
- •KYNB is profitable (3967.77% net margin) while ESLA runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ESLA | KYNB |
|---|---|---|
| P/S ratio | N/A | 5.22 |
Profitability
| Metric | ESLA | KYNB |
|---|---|---|
| Gross margin | 0.00% | 91.37% |
| Operating margin | 0.00% | -712.66% |
| Net margin | 0.00% | 3967.77% |
| ROIC | N/A | -78.16% |
Growth (annualized)
| Metric | ESLA | KYNB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -51.49% |
| Total return CAGR (5Y) | -46.34% | -52.67% |
Frequently asked
- Is ESLA or KYNB more profitable?
- KYNB runs the higher net margin — ESLA at 0.00% versus KYNB at 3967.77%.
- How have ESLA and KYNB total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and KYNB delivered -52.67% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.